Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Decision on Stock Companies' Management of Medical Institutions Remains Unpredictable
December 23, 2002
- NEW PRODUCTS IN BRIEF
December 23, 2002
- Bill on New Drug Organization Clears the Diet
December 23, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
December 23, 2002
- No Meaningful Progress on Mutual Recognition: MOSS Follow-up Talks
December 23, 2002
- OTC NEWS IN BRIEF
December 23, 2002
- Strong Incentives Essential to Development of Innovative Drugs: CEFP
December 23, 2002
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 23, 2002
- REGULATORY NEWS IN BRIEF
December 23, 2002
- DIAGNOSTIC NEWS IN BRIEF
December 23, 2002
- Tracheal Intubation by Lifeguards to Be Permitted from July 2004
December 23, 2002
- EFPIA Wishes to Actively Participate in Japanese Healthcare Reform Talks
December 23, 2002
- Korosho to Classify Medical Fees into Doctors' and Hospitals' Fees
December 23, 2002
- Mevalotin's Patent Expiration Brings Sankyo No. 1 Issue
December 23, 2002
- SCN Group to Integrate Internet Services for Medical Professionals
December 23, 2002
- Fuso Extends Anticancer Gene Therapy Research Agreement with GenVec
December 23, 2002
- EPS Group Separates Its CRO and SMO Businesses
December 23, 2002
- WORLD NEWS IN BRIEF
December 23, 2002
- Banyu to Maintain Sales of Lipovas Based on Evidence from Clinical Trials
December 23, 2002
- PM Reiterates Support for Stock Companies' Management of Medical Facilities: Diet
December 23, 2002
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…